Lange Louis G's Form 4 filing
NewAmsterdam Pharma Co N.V.NAMS · filed Feb 21, 2024
- Accession no.
- 0000950170-24-018045
- Filed
- Feb 21, 2024
- Trade date
- Feb 13, 2024
- Filing delay
- 8 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $95.0K. It was filed 8 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lange Louis GCIK 0001238401 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | Ordinary Shares | PPurchaseAcquired | +5,000 | $19.00 | +$95,000 | 24,878 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.